Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +1.11%72 3-Year EPS without NRI Growth Rate is 71.70% as of Jun. 2026, which is 237% above its 10-year median of 21.30. GuruFocus rates FRA:PHS with a GF Score™ of 72/100 and a GF Value™ of €6.81 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 788 Drug Manufacturers companies, PhotoCure ASA ranks better than 94.67% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 71.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of PhotoCure ASA was 71.70% per year. The lowest was -22.30% per year. And the median was 21.30% per year.
PhotoCure ASA (FRA:PHS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
PhotoCure ASA 3-Year EPS without NRI Growth Rate Related Terms
FRA:PHS vs ZTS, UTHR, VTRS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's 3-Year EPS without NRI Growth Rate falls into.
PhotoCure ASA 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 71.70% mean?
PhotoCure ASA (FRA:PHS) has a 3-Year EPS without NRI Growth Rate of 71.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for PhotoCure ASA and its competitors. This is 237% above median its historical median of 21.30. According to the industry distribution chart, PhotoCure ASA ranks #42 out of 788 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is PhotoCure ASA's 3-Year EPS without NRI Growth Rate too high?
PhotoCure ASA's current 3-Year EPS without NRI Growth Rate of 71.70% is 237% above median its 10-year median of 21.30. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. PhotoCure ASA's value of 71.70% is 646.9% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #42 out of 788 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PhotoCure ASA has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's 3-Year EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #42 out of 788 companies for 3-Year EPS without NRI Growth Rate. This places PhotoCure ASA in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.60. PhotoCure ASA's value of 71.70% is 646.9% above this benchmark. While the company's 10-year median is 21.30 vs. the industry median of 9.60, PhotoCure ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current 3-Year EPS without NRI Growth Rate of 71.70% is 646.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current 3-Year EPS without NRI Growth Rate is 71.70%, which is 237% above median its own 10-year median of 21.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Significantly Undervalued. The stock's GF Value™ is €6.81, compared to a current price of €4.55 — trading 33.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 71.70%, which is 237% above median its 10-year median of 21.30 and 646.9% above the Drug Manufacturers industry median of 9.60. PhotoCure ASA's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current 3-Year EPS without NRI Growth Rate is 71.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €4.55 is trading 33.2% below its estimated GF Value™ of €6.81.
GuruFocus considers PhotoCure ASA to be Significantly Undervalued.
Key valuation signals for FRA:PHS:
3-Year EPS without NRI Growth Rate: 71.70% (237% above median its 10-year median of 21.30)
GF Value™: €6.81 vs. price of €4.55 (33.2% below fair value)
Industry Position: 646.9% above the Drug Manufacturers median (#42 of 788)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
72GF Score
Get the complete analysis for FRA:PHS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
